Skip to main
SER

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics is a promising company with valuable products and potential market opportunities in the treatment of neurological diseases. Its current product, SER-252, has shown promising results in clinical trials, and the company's POZ platform has the potential to revolutionize drug delivery in this industry. With successful Phase 1b results and potential for future partnerships, Serina may see significant growth and success in the future as it addresses a pressing need for better treatments in the Parkinson's disease market.

Bears say

Serina Therapeutics is a clinical-stage biotechnology company with a negative outlook due to its focus on a single product candidate, SER-252, for advanced Parkinson's disease. While the market for this product is large and in need of better treatment options, the company faces significant regulatory and technical challenges with its proprietary POZ polymer drug delivery platform. Furthermore, the company's pipeline is limited beyond SER-252 and it is dependent on a single source of revenue from grant funding. This, combined with its recent clinical hold and potential for future delays, make Serina Therapeutics a high-risk, low-reward investment.

SER has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 1 analysts, SER has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.